B
Beijing Mabworks Biotech
Biopharmaceutical company developing antibody therapies for autoimmune diseases and cancer
About Beijing Mabworks Biotech
Beijing Mabworks Biotech (MabWorks) is a biopharmaceutical company founded in 2003 that discovers, develops, manufactures and commercializes therapeutic antibodies for oncology and autoimmune indications. The company has built proprietary antibody technology platforms covering the full discovery-to-development pipeline: an ADCC-enhanced antibody platform, a multispecific antibody platform, an antibody discovery and optimization platform, a half-life extended antibody platform, and a CMC and manufacturing platform. These enable the design and selection of differentiated antibody drug candidates with improved efficacy, safety and pharmacokinetic properties.
MabWorks' lead product, Bejescin (MIL62), a third-generation recombinant humanized anti-CD20 antibody developed on its ADCC-enhanced platform, was approved by China's NMPA in February 2026 for neuromyelitis optica spectrum disorder (NMOSD) and primary membranous nephropathy (pMN), becoming the world's first drug approved for the pMN indication and the first domestically developed NMOSD treatment in China. The pipeline also includes MBS303/MSC303, a CD20/CD3 T-cell engager, MBS314, a GPRC5D/BCMA/CD3 multispecific antibody, and MIL116, an anti-APRIL antibody for IgA nephropathy, among more than 15 clinical and preclinical programs.
The company operates an R&D-driven model that combines internal development with out-licensing and strategic collaborations with pharmaceutical partners in China and globally, including an exclusive licensing agreement with Climb Bio for an anti-APRIL antibody outside Greater China. MabWorks is traded on the National Equities Exchange and Quotations (NEEQ: 874070) and is headquartered in the Beijing Economic-Technological Development Area.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2020 | $160M | $640M | CITIC Securities · LYZZ Capital · Lake Bleu Capital · Sealand Innovation | ↗ |
| SERIES BOther financing | Jan 2017 | $39M | $156M | ShenZhen GTJA Investment Group | — |
Growth signals
Latest recorded traffic for Beijing Mabworks Biotech is 330 monthly website visits, down 62.9% over the last three months. Beijing Mabworks Biotech's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Mabworks Biotech in the Dongcheng District ecosystem
The Beijing Mabworks Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Med-Fine Capital- SGShenZhen GTJA Investment Group
Series B and later9 investors entered at this stage
CICC
CITIC Securities- LCLYZZ Capital
Lake Bleu Capital- SISealand Innovation
E-Town Capital
Yue Xiu Enterprises- HCHuge Capital
SDIC Unity Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Mabworks Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Mabworks Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










